Blog Archives

Diabetes: No end to SGLT2-inhibitor drugs side effects

01 September 2018 – The American Food and Drug Administration (FDA)  is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Read more ›

Tags: , , , , , , , , , , , , , , , , , , ,

Sodium-glucose cotransporter-2 (SGLT2) inhibitors in Type-2 Diabetes: Risk of acute kidney injury

June 16, 2016 – The sodium-glucose cotransporter 2 (SGLT2) is a protein that is encoded by the SLC5A2 gene. SGLT2 is one member of a larger family of sodium-glucose cotransporters which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. 

Read more ›

Tags: , , , , , , , , , , , , ,

SGLT2 Inhibitors and ketoacidosis: Warnings about too much acid in the blood and serious urinary tract infections included in new drug labels

December 5, 2015 – A safety review by the American Food and Drug Administration (FDA) has resulted in the addition of specific warnings to the drug labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections.

Read more ›

Tags: , , , , , , , , , , , , , ,

Type 2 Diabetes: Risk for bone fracture and decreased bone mineral density under canagliflozin therapy

 September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA)  has just strengthened the warning for the type 2 diabetes medicines containing  canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone fractures, and added new information about decreased bone mineral density in afflicted patients.

Read more ›

Tags: , , , , , , , ,

Medicines based on SGLT2 inhibiton may result in ketoacidosis, a serious condition of too much acid in the blood

May 15, 2015 – The American Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines Canagliflozin (Invokana), Dapagliflozin (Farxiga), and Empagliflozin (Jardiance) may lead to ketoacidosis,

Read more ›

Tags: , , , , , , , ,

thasso: community

thasso: conditions

thasso post: magazine

View my Flipboard Magazine.

thasso: chat

[sac_happens]

thasso: tweets

thasso: categories

thasso: archives

Top